Table 2.
Characteristics of participants (PLHIV’ data from the studies included in the systematic review and meta‐analysis)
| Author/year | PLHIV (N) | Age $ | Females (N) % | CD4 count $ | BMI $ | Tcho $ | TG $ | AST $ | ALT $ | T2DM $ | AHT % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Crum‐Cianflone 2009 | 216 | 39.6 (11.1) | 12 (5.6) | 535.2 (247.5) | 26 (4.1) | 185.9 (41.9) | 172.1 (158.3) | NR | NR | 11 (5.1) | 49 (22.7) |
| Sterling 2013 | 14 | 45 (10) | 4 (29) | 614 (357) | 29.9 (7.4) | 172 (38) | 235 (180) | 76 (46) | 94 (58) | 3 (21) | NR |
| Nishijima 2014 | 435 | 40 (35–50) | 29 (7) | 349 (203–512) | 22.1 (20.2–24.9) | 175 (150–205) | 162 (104–233) | 25 (19–37) | 26 (17–47) | 22 (5) | 86 (20) |
| G Lui 2016 | 80 | 54 (11) | 6 (8) | 503 (248) | 23.6 (3.9) | 185.6 (38.6) | 159.29 (123.8–274.3) | 26 (22–32) | 86 (69–107) | 39 (48.8) | 33 (41.3) |
| Kardashian 2017 | 122 | NR | 58 (47.5) | NR | NR | NR | NR | NR | NR | NR | NR |
| Lombardi 2017 | 156 | 47.5 (8.5) | 13 (8) | 683 (4–1900) | NR | NR | NR | 41 (22–299) | 56 (29–372) | 17 (11) | 28 (18.2) |
| Price 2017 | 329 | 52 (47–57) | 0 (0) | 598 (438–776) | 26 (23–29) | NR | 130 (91–205) | 24 (20–31) | 25 (18–35) | 39 (12) | 152 (48) |
| Aepfelbacher 2019 | 46 | 27 (3.1) | 28 (61) | 605 (400) | 27 (7) | 165 (41) | 109 (73) | 25 (12) | 23 (16) | NR | NR |
| Lallukka‐Brück 2019 | 41 | 41.9 (1.3) | 7 (17) | NR | 23.1 (0.5) | NR | 168.1 (141.59–292.04) | 32 (28–44) | 30 (23–50) | 0 (0) | NR |
| Vujanović 2019 | 88 | 39.94 (9.91) | 0 (0) | NR | 24.76 (3.58) | NR | 290.27 (364.6) | 25.1 (12.3) | 30.5 (22.8) | NR | NR |
| Ajmera 2020 | 70 | 48.6 (10.2) | 7 (10) | 791 (688) | 26.9 (4.6) | 193.5 | 116.5 (48) | 24.5 (20) | 30.5 (19) | 11 (15.7) | NR |
| Ferri Pezzini 2020 | 98 | 49 (11) | 45 (46) | 657.5 (118–208) | 25.45 (23.6–28.2) | 188.6 (34) | 156 (118–218) | 21 (17–26) | 22 (16–30) | 35 (35.7) | 27 (27.6) |
| Kaplan 2020 | 232 | 54 (9) | 55 (23.7) | NR | NR | NR | NR | NR | NR | 44 (18.9) | 98 (42.2) |
| Kirkegaard 2020 | 453 | 52.4 (46.8–61) | 65 (14.3) | 690 (520–884) | 24.7 (22.4–27.5) | 189.2 (162.1–220) | 159.3 (115–247.8) | NR | 26 (20–34) | 33 (7.3) | NR |
| Rasoulinejad 2020 | 100 | 39.9 (9.5) | 51 (51) | 610 | NR | NR | NR | NR | NR | 1 (1) | NR |
| Bischoff 2021 | 319 | 47.5 (11.5) | 72 (22.5) | NR | 24.9 (4.5) | 197.6 (43.1) | 187.6 (148.3) | 24.5 (14.2) | 35.4 (18.1) | 19 (6) | 65 (20.4) |
| Fonseca de Almeida 2021 | 451 | 45 (36–53) | 272 (60.3) | 665 (421–881) | 25 (23–29) | 185 (158–219) | 124 (84–171) | 25 (20–33) | 29 (23–43) | 46 (10.2) | 100 (22.2) |
| Jongraksak 2021 | 150 | 45.83 (9.54) | 67 (44.7) | 562 (217.7) | 22.77 (3.57) | 202.23 (42.78) | 149.23 (98.92) | 31.36 (10.27) | 37.97 (34.14) | 10 (6.7) | NR |
| Liu danping 2021 | 361 | 38 (31–48) | 17 (4.7) | 459 (327–633.5) | 22.64 (21.04–24.73) | 180.57 (155.82–205.7) | 143.36 (95.58–238.05) | NR | 29 (20–51) | 29 (8.03) | 36 (9.9) |
| Arka De 2022 | 100 | 36.8 (10.4) | 35 (35) | NR | 22.9 (4.3) | NR | 187.2 (60.7) | NR | NR | 4 (4) | 8 (8) |
| Busca 2022 | 69 | 50 (44–54) | 13 (9) | 740 (593–930) | 27 (24–30) | 182 (159–203) | 147 (97–213) | 36 (28–43) | 50 (41–77) | 63 (44) | 57 (39) |
| Lemoine 2022 | 402 | 55 (50–61) | 62 (15) | 603 (510–832) | 27 (23.6–28.7) | NR | 141.6 (97.3–221.2) | 29 (23–37) | 34 (24–50) | NR | NR |
| Michel 2022 | 245 | 52 (42–58) | 71 (29) | 727 (516–901) | 25 (22.4–28.5) | 202 (177–229) | 133 (90–191) | 26 (23–31) | 23 (18–32) | 27 (11) | 75 (30.6) |
| Sebastiani 2022 | 1749 | 50.2 (10.4) | 446 (25.5) | NR | NR | NR | NR | NR | NR | 595 (34) | NR |
Abbreviations: AHT, arterial hypertension; Tcho, total cholesterol; TG, triglycerides; T2DM, type 2 diabetes mellitus.
– $: Data presented in means/medians (SD/IQR); %: data presented in frequencies and percentages.